(Boursier.com) — The company The Goldman Sachs Group, Inc.based in the state of Delaware, United States, has crossed the threshold of 5% of the capital and voting rights of Gensight Biologics SA on February 13, 2024. After this crossing, it indirectly holds, via Goldman Sachs International, 5,325,415 shares of Gensight Biologics SA, or 6.80% of the capital and voting rights. This crossing results from an off-market acquisition of shares and an increase in the number of shares held by assimilation. Goldman Sachs International also crossed the same thresholds individually.
©2024 Boursier.com
This content was produced by the AI under the supervision of a journalist from the editorial staff. Please note that this declaration is drawn up under the responsibility of the declarant, the publication of this notice not implying verification by the AMF or Boursier.com of the information communicated.